Clinical Trials Logo

Clinical Trial Summary

This is a study proposal for a clinical trial to evaluate the effectiveness of a reduced dose of antenatal betamethasone (a steroid medication) in preventing respiratory problems in late preterm infants (born between 34 and 36 weeks of gestation). The study will be conducted in medical centers in Israel and will involve women who are at high risk for delivering a late preterm infant. The participants will be randomly assigned to receive either a full dose (12 mg) or a quarter dose (3 mg) of betamethasone, administered 24 hours apart. The main outcome measure of the study will be the incidence of respiratory problems or neonatal death within 72 hours of delivery in the two groups. The study is designed to determine if the reduced dose of betamethasone is non-inferior (i.e., not significantly worse) than the full dose in preventing respiratory problems in late preterm infants.


Clinical Trial Description

Antenatal corticosteroids (ACS) are a type of steroid medication that is administered to pregnant women at risk of preterm birth in order to reduce the risk of respiratory distress syndrome (RDS) and other complications in the newborn. ACS were first demonstrated to be effective in a controlled trial conducted in the 1970s by Liggins and Howie, who used a combination of betamethasone at a dose of 12 mg given in two doses 24 hours apart. Since then, numerous randomized controlled trials and meta-analyses have shown that ACS can significantly reduce neonatal death, RDS, intraventricular hemorrhage, necrotizing enterocolitis, and the need for respiratory support and neonatal intensive care unit admission in preterm infants. ACS are now recommended for use in virtually all pregnancies at risk of preterm delivery between 24 and 34 weeks of gestation. The use of ACS in late preterm pregnancies (between 34 and 37 weeks) has also been studied, with mixed results. The largest study to date, the ALPS trial, found that ACS reduced composite adverse outcomes and respiratory morbidity in late preterm infants, but did not significantly reduce the risk of RDS or mortality. The American Congress of Obstetricians and Gynecologists has recommended the use of ACS in late preterm pregnancies, but with caution due to the potential for adverse effects such as hypoglycemia. Long-term follow-up studies are needed to evaluate the potential long-term effects of ACS in late preterm infants. In this the participants will be randomly assigned to receive either a full dose (12 mg) or a quarter dose (3 mg) of betamethasone, administered 24 hours apart. The main outcome measure of the study will be the incidence of respiratory problems or neonatal death within 72 hours of delivery in the two groups. The study is designed to determine if the reduced dose of betamethasone is non-inferior (i.e., not significantly worse) than the full dose in preventing respiratory problems in late preterm infants. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05698966
Study type Interventional
Source Rambam Health Care Campus
Contact Ron Beloosesky, MD
Phone 0509205759
Email tomor2304@yahoo.com
Status Recruiting
Phase N/A
Start date January 1, 2022
Completion date January 1, 2028

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06168149 - The Relationship of Fetal Lung Elastography Values With the Development of Respiratory Distress in Cases of Preterm Labor
Completed NCT02538718 - Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor N/A
Not yet recruiting NCT05864066 - Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals
Terminated NCT03715530 - Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women N/A
Recruiting NCT03638037 - Correlation Between Maternal Vitamin D Level And Preterm Birth
Recruiting NCT03992534 - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth Phase 1
Withdrawn NCT03122704 - Group B Streptococcus (GBS) Infection and in Preterm Labor Women Conceived Through IVF N/A
Completed NCT02536352 - Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being Early Phase 1
Recruiting NCT01518816 - Role of Serum Total Antioxidant Level in Preterm Labor N/A
Recruiting NCT04590677 - Prediction of the Onset of Term and Preterm Labour
Completed NCT03112018 - Strengthening Facility-based Intrapartum/Immediate Newborn Care to Reduce Mortality of Preterm Infants in Migori County, Kenya and Busoga Region, Uganda N/A
Active, not recruiting NCT04301518 - Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs N/A
Completed NCT03785795 - Multichannel EMG Diagnosing True Preterm Labor
Withdrawn NCT02351310 - Effectiveness of ACS in Extreme Preemies Phase 3
Not yet recruiting NCT01985594 - Utrogestan Versus Nifedipine as Tocolysis for Preterm Labor: a Randomised Controlled Trial Phase 2
Not yet recruiting NCT04532086 - Uterocervical Angle and Preterm Labour
Completed NCT04605172 - Lockdown Impact on Spontaneous Premature Birth in a Level III NICU
Recruiting NCT04417595 - Investigating N-3 Fatty Acids to Prevent Neonatal Tobacco-related outcomeS Phase 2
Completed NCT03923023 - Impact of the PREEMI Package on Neonatal Mortality
Recruiting NCT06157203 - Labor Status Monitor for Diagnosing True vs False Labor in Preterm Patients